Curanex (Nasdaq: CURX) targets cancer cachexia in expanded pipeline
Rhea-AI Filing Summary
Curanex Pharmaceuticals Inc. is expanding its drug development pipeline to add cancer cachexia as a new core indication alongside six existing targets such as ulcerative colitis and nonalcoholic fatty liver disease. Cancer cachexia is a severe cancer‑related wasting syndrome with no approved U.S. therapies.
The company cites significant unmet medical need and growing recognition of cancer cachexia, which may affect up to 80% of patients with advanced cancer depending on type and treatment response. Curanex references research estimating the global cancer cachexia market at about $2.54 billion in 2024, projected to reach $3.90 billion by 2033.
Curanex’s lead candidate, Phyto‑N, remains in FDA‑required preclinical studies ahead of a planned IND submission for ulcerative colitis, while management evaluates broader opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline.
Positive
- None.
Negative
- None.
Insights
Curanex broadens its development focus to cancer cachexia, highlighting a large unmet market but remains preclinical.
Curanex is adding cancer cachexia to its core indications, positioning itself more squarely in supportive oncology. Management highlights that cachexia can affect up to 80% of advanced cancer patients, with serious impact on strength, therapy tolerance and quality of life.
The company cites a global cancer cachexia market of about $2.54 billion in 2024, projected to $3.90 billion by 2033, underscoring the commercial potential. However, its lead asset Phyto‑N is still in preclinical testing before a planned IND for ulcerative colitis, so timelines and clinical risk remain early‑stage.
Strategically, Curanex frames cancer cachexia as aligned with its focus on serious diseases involving inflammation, metabolic disruption and physical decline. Future disclosures on IND submissions, initial oncology‑related studies and any partnering activity will be important to understand how this expanded focus translates into concrete development milestones.
8-K Event Classification
Key Figures
Key Terms
cancer cachexia medical
Investigational New Drug (IND) regulatory
preclinical studies medical
supportive oncology medical
forward-looking statements regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
Curanex Pharmaceuticals Inc (the “Company”) today issued a press release announcing that it is expanding its drug development pipeline that previously encompassed six core indications: (ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout) and will focus on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function.
A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 7.01, as well as Exhibit 99.1 referenced herein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release of Curanex Pharmaceuticals Inc dated April 2, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Curanex Pharmaceuticals Inc | ||
| Date: April 2, 2026 | By: | /s/ Jun Liu |
| Name: | Jun Liu | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
Company
expands strategic focus into one of oncology’s
most urgent supportive-care challenges
Jericho, New York, April 2, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is expanding its drug development pipeline that encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function.
Cancer cachexia is widely recognized as one of the most serious complications in oncology and is estimated by the National Cancer Institute to occur in up to 80% of patients with advanced cancer, depending on cancer type and response to treatment. The syndrome can severely reduce strength, impair quality of life and limit a patient’s ability to tolerate therapy. Despite its significant clinical burden, there are currently no approved therapies for cancer cachexia in the United States.
Curanex believes the combination of major unmet need, limited treatment options and growing clinical recognition supports a significant long-term commercial opportunity in cancer cachexia. According to Grand View Research, the global cancer cachexia market was approximately $2.54 billion in 2024 and is projected to grow to $3.90 billion by 2033.
Curanex’s lead program, Phyto-N, is currently advancing through preclinical studies in preparation for a planned Investigational New Drug (IND) submission for ulcerative colitis. As it advances that program, the Company is also evaluating additional development opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline.
Curanex Chief Executive Officer, Jun Liu, said “Cancer cachexia remains one of the largest unmet needs in supportive oncology, with serious consequences for patients and very limited treatment options. We believe this area represents a meaningful opportunity for focused drug development and an important step in the evolution of Curanex into a broader therapeutics development company.”
Curanex management believes that the focus on treatment of cancer cachexia aligns with the Company’s broader focus on treatment of serious diseases involving inflammation, metabolic disruption and physical decline. While Curanex remains committed to advancing its lead ulcerative colitis program, the Company believes that by expanding its long-term pipeline potential by also focusing on cancer cachexia treatment, the Company will strengthen its positioning as an emerging therapeutics company.
About Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc. is a development-stage therapeutics company headquartered in Jericho, New York. The Company is advancing drug development programs for serious diseases with significant unmet medical need. Its lead candidate, Phyto-N, is currently being advanced through FDA-required preclinical studies in preparation for a planned IND submission for ulcerative colitis. Curanex is also evaluating broader development opportunities intended to expand its long-term therapeutic pipeline.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions.
The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors to read “Risk Factors” section of the Company’s Annual Report on Form 10-K dated March 30, 2026 (Inline Viewer: CURANEX PHARMACEUTICALS INC 10-K 2025-12-31) and risk factors contained in other filings with the Securities and Exchange Commission (the “SEC”) to gain understanding of the important factors that could cause actual results to differ materially from the anticipated results and projections about future events contained in this press release.
Contact:
Curanex
Pharmaceuticals Inc
Tel: (212) 671-1020 / (718) 673-6078
Email: ir@curanexpharma.com